Provided by Tiger Fintech (Singapore) Pte. Ltd.

Precision Biosciences Inc

4.88
+0.19004.05%
Post-market: 4.880.00000.00%19:28 EDT
Volume:62.65K
Turnover:299.29K
Market Cap:54.11M
PE:-1.75
High:4.92
Open:4.66
Low:4.66
Close:4.69
Loading ...

Precision BioSciences Inc : Bmo Raises to Outperform From Market Perform

THOMSON REUTERS
·
10 Jan

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner Iecure in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (Otc) Deficiency

THOMSON REUTERS
·
09 Jan

Precision BioSciences Inc - Ecur-506 Generally Well Tolerated With No Significant Safety Concerns

THOMSON REUTERS
·
09 Jan

Iecure Reports Complete Clinical Response in First Infant Dosed With Its in Vivo Gene Editing Candidate Ecur-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (Otc) Deficiency

THOMSON REUTERS
·
09 Jan

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Business Wire
·
09 Jan

BRIEF-Precision Biosciences Expects Cash Runway Into H2 2026

Reuters
·
08 Jan

Precision BioSciences Inc - Expects Cash Runway Into Second Half of 2026

THOMSON REUTERS
·
08 Jan

BRIEF-Precision Biosciences Receives Approval In Hong Kong To Expand Pbgene-Hbv Phase 1 Eliminate-B Trial

Reuters
·
18 Dec 2024

Precision BioSciences Receives Approval in Hong Kong to Expand Pbgene-Hbv Phase 1 Eliminate-B Trial for the Treatment of Chronic Hepatitis B

THOMSON REUTERS
·
18 Dec 2024

Precision BioSciences Inc - U.S. Ind for Pbgene-Hbv Anticipated in 2025

THOMSON REUTERS
·
18 Dec 2024

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Business Wire
·
18 Dec 2024

Precision BioSciences to Participate in Upcoming November Investor Conferences

Business Wire
·
21 Nov 2024